Everyone loves a winner, but who are they? Let us help you figure it out. Each Friday, we will provide a quick rundown — of individuals, companies, what have you — that accomplished something worth noting. But to be fair, we will also point out those who, well, had a rough time. And if you have a nomination, send us a note. We would not want anyone to feel left out, even the losers.
Novo Nordisk scored a modest publicity coup by very publicly committing to limiting price hikes on its medicines to single-digit increases annually. The company is now the second big drug maker to do so, after Allergan. And while many people may not have read his note, Novo president Jakob Riis carefully and calmly used the opportunity to skewer pharmacy benefit managers and insurers, which the pharmaceutical industry is increasingly blaming for the rising cost of medicines.